北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第一临床医学院  > 肿瘤化疗科  > 期刊论文
学科主题: 临床医学
题名:
Phase II trial of capecitabine combined with docetaxel in previously treated patients with non-small cell lung cancer: A randomized controlled study
作者: Lin, Qiang1; Meng, Fan-Jie1; Liu, Yue&prime1; e(1)1; Wang, Na1; Ren, Xiao-Cang1; Chen, Xue-Ji1; Ge, Xiao-Hui2; Liu, Chao-Xing3; Hui, Jing1; Wang, Dong-Ying1; Cao, Bin1; Zhao, Yannan1
关键词: non-small cell lung cancer ; chemotherapy ; second-line therapy ; capecitabine ; docetaxel
刊名: ONCOLOGY LETTERS
发表日期: 2012-04-01
DOI: 10.3892/ol.2012.575
卷: 3, 期:4, 页:761-766
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology
研究领域[WOS]: Oncology
关键词[WOS]: 2ND-LINE TREATMENT ; BREAST-CANCER ; COMBINATION ; THERAPY ; TUMORS
英文摘要:

Docetaxel alone has been confirmed to be beneficial to patients with advanced previously treated non-small cell lung cancer (NSCLC). However, the duration and survival time is short. The study of two-agent combination regimens has important clinical significance. We conducted this randomized controlled phase II trial to comparatively evaluate the efficacy and side effects of capecitabine combined with docetaxel in previously treated patients with NSCLC. Patients with previously treated NSCLC who failed first-line chemotherapy were randomized into two groups; one received capecitabine combined with docetaxel (XT group) and the other received docetaxel alone (T group). Patients in the XT group received chemotherapy as follows: capecitabine 625 mg/m(2), p.o. bid, days 5-18; and docetaxel 30 mg/m(2), days 1 and 8, while patients in the T group received docetaxel 35 mg/m(2) on days I and 8. The primary endpoint was time to progression (TTP), and secondary endpoints were overall survival (OS), response rate (RR) and disease control rate (DCR). Forty-eight patients were recruited (23 in the Xi group and 25 in the T group). TIP, median survival time (MST) and I-year OS rate in the XT group and the T group were 7 months, 12 months, 47.6% and 3 months, 12 months, 39.6%, respectively. The TTP in the XT group was significantly longer compared to that in the T group (chi(2)=-4.763, p=0.029). The RR and DCR in the XT group and T group were 13.0% (3/23), 78.3% (18/23) and 12.0% (3/25), 76% (19/25), respectively. The difference was not significant (p>0.05). The major side effects observed in the two groups were neutropenia, fatigue and nausea, and toxicities were mild to modest. No severe cases of hand-foot syndrome were observed in the XT group. In conclusion, compared with docetaxel alone, capecitabine combined with docetaxel for patients with previously treated NSCLC achieved a significantly longer TIT and this regimen was well tolerated. The relatively high median TTP, 1-year OS rate and DCR encourage further evaluation of this regimen in a randomized phase III trial.

语种: 英语
所属项目编号: 072761711
项目资助者: Science and Technology Department of Hebei Province, China
WOS记录号: WOS:000301307600005
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/51934
Appears in Collections:北京大学第一临床医学院_肿瘤化疗科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Hebei Med Univ, Affiliated N China Petr Bur, Gen Hosp, Dept Oncol, Renqiu City 062552, Hebei, Peoples R China
2.Hebei Univ, Affiliated Hosp, Dept Radiat Oncol, Baoding 071000, Hebei, Peoples R China
3.Beijing Univ, Hosp 1, Dept Radiat Oncol, Beijing 10034, Peoples R China

Recommended Citation:
Lin, Qiang,Meng, Fan-Jie,Liu, Yue&prime,et al. Phase II trial of capecitabine combined with docetaxel in previously treated patients with non-small cell lung cancer: A randomized controlled study[J]. ONCOLOGY LETTERS,2012,3(4):761-766.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Lin, Qiang]'s Articles
[Meng, Fan-Jie]'s Articles
[Liu, Yue&prime]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Lin, Qiang]‘s Articles
[Meng, Fan-Jie]‘s Articles
[Liu, Yue&prime]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace